ArticleHaematologica2018
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- Artificial intelligence-based prognostic models in acute myeloid leukemia: systematic review and meta-analysis.Blood neoplasia · 2026Article
- MORC2 promotes acute myeloid leukemia by silencing LINE-1 retrotransposon.Functional & integrative genomics · 2026Article
- Multi-omics classification of acute myeloid leukemia guides drug combinations to overcome Venetoclax resistance.Cancer drug resistance (Alhambra, Calif.) · 2026Article
- Integrative single-cell and bulk transcriptomics define polyamine-associated cell states in acute myeloid leukemia and implicate CCT6A in polyamine homeostasis.Frontiers in immunology · 2026Article
- LTF promotes central nervous system leukemia progression via neutrophil serine proteases.Frontiers in pharmacology · 2026Article
- Review
- Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia.Cancer research and treatment · 2025Article
- ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche.Nature communications · 2025Article
- Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway.Nature communications · 2025Article
- Artificial intelligence and anti-cancer drugs' response.Acta pharmaceutica Sinica. B · 2025Review
- A Five-Gene Signature for the Prediction of Event-Free Survival of Both Pediatric and Adult Acute Myeloid Leukemia.Diagnostics (Basel, Switzerland) · 2025Article
- Metabolism in hematology: Technological advances open new perspectives on disease biology and treatment.HemaSphere · 2025Review
- Prognostic value of natural killer T cell related genes in acute myeloid leukemia.Cancer cell international · 2025Article
- Lysosomal cation channel TRPML1 suppression sensitizes acute myeloid leukemia cells to chemotherapeutics by inhibiting autophagy.Molecular and cellular biochemistry · 2025Article
- The role of SLC22A4 in Acute Myeloid Leukaemia.Mediterranean journal of hematology and infectious diseases · 2025Article
- Development and validation of a disulfidptosis-related genes signature for predicting outcomes and immunotherapy in acute myeloid leukemia.Frontiers in immunology · 2025Article
- Identifying acute myeloid leukemia subtypes based on pathway enrichment.Frontiers in pharmacology · 2025Article
- Deciphering cell states and the cellular ecosystem to improve risk stratification in acute myeloid leukemia.Briefings in bioinformatics · 2024Article
- Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.Innovation (Cambridge (Mass.)) · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary therapy resistance is a major problem in acute myeloid leukemia treatment. We set out to develop a powerful and robust predictor for therapy resistance for intensively treated adult patients. We used two large gene expression data sets (n=856) to develop a predictor of therapy resistance, which was validated in an independent cohort analyzed by RNA sequencing (n=250). In addition to gene expression markers, standard clinical and laboratory variables as well as the mutation status of 68 genes were considered during construction of the model. The final predictor (PS29MRC) consisted of 29 gene expression markers and a cytogenetic risk classification. A continuous predictor is calculated as a weighted linear sum of the individual variables. In addition, a cut off was defined to divide patients into a high-risk and a low-risk group for resistant disease. PS29MRC was highly significant in the validation set, both as a continuous score (OR=2.39,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.